Introducing Levagen: Clinically studied palmitoylethanolamide for joint discomfort
An estimated 91.2 million adults have been medically diagnosed with some form of arthritis or symptoms related to it. With concerns about pharmaceutical side effects, consumers are looking for alternative solutions to addressing joint health.
Introducing Levagen® by Gencor, an innovative PEA ingredient that utilizes the endocannabinoid system for supporting joint function, reducing joint stiffness and providing joint comfort. Levagen is a clinically studied, self-affirmed GRAS ingredient. Usually isolated from peanuts, egg yolk and soybeans, PEA is produced in the body as a biological response and as a repair mechanism for inflammation response.
Fill out the form and download Gencor’s product brochure to learn more about Levagen and Levagen Plus™.